Sustiva oral solution discontinuation
Bristol-Myers Squibb is discontinuing Sustiva (efavirenz) 30 mg/ml oral solution in the UK and Ireland on 31 October 2015. As a result of the Sustiva oral solution discontinuation, the paediatric indication for the Sustiva hard capsules and film coated tablets has been extended to include children from three months of age who weigh at least 3.5kg.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068424
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com